Table 1.
New possible drugs
| Pathways | Target | Pathophysiology | Medication | Type/class |
|---|---|---|---|---|
| S1P signalling | S1P receptor agonist | Proliferation, migration, apoptosis, inflammation and fibrogenesis | Fingolimod | Pro-drug |
| CBP/β‐catenin | CBP/β‐catenin complex | Proliferation, migration, apoptosis, and fibrogenesis | C-82 | Nonhormone, β‐catenin inhibitor |
| CBP/β‐catenin | CBP/β‐catenin complex | Proliferation, migration, apoptosis, and fibrogenesis | ICG-001 | Nonhormone, β‐catenin inhibitor |
| Wnt/β‐catenin | Tcf/β‐catenin complex | Proliferation, migration, invasion & fibrogenesis | PKF115‐584/CGP049090 | Natural product |
|
TGF‐β1‐stimulated/activation of MAPK and Smad pathway & E2/ER/VEGF |
/ | Proliferation, migration, invasion & fibrogenesis | EGCG | Natural product, catechin |
| RLX-2 | Decreased the phosphorylation of p38MAPK in ESCs | Fibrogenesis and inflammation | Relaxin 2 | Produced by the corpus luteum and placenta |